BioNTech SE (BNTX)
| Market Cap | 26.97B |
| Revenue (ttm) | 3.38B |
| Net Income (ttm) | -404.93M |
| Shares Out | 240.40M |
| EPS (ttm) | -1.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,014 |
| Open | 111.50 |
| Previous Close | 111.00 |
| Day's Range | 111.50 - 111.50 |
| 52-Week Range | 79.88 - 131.49 |
| Beta | 1.24 |
| Analysts | Strong Buy |
| Price Target | 139.60 (+24.42%) |
| Earnings Date | Aug 4, 2025 |
About BNTX
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph... [Read more]
Analyst Forecast
According to 18 analysts, the average rating for BNTX stock is "Strong Buy." The 12-month stock price target is $139.6, which is an increase of 24.42% from the latest price.
News
CureVac settles patent dispute litigation with Pfizer and BioNTech
CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and BioNTech related to mRNA-based COVID-19 vaccines.
These Analysts Revise Their Forecasts On BioNTech After Q2 Results
BioNTech SE BNTX reported a narrower loss for the second quarter on Monday.
BioNTech SE (BNTX) Q2 2025 Earnings Call Transcript
BioNTech SE (NASDAQ:BNTX) Q2 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Douglas Maffei - Investor Relations Ozlem Tureci - Co-Founder, Chief Medical Officer & Member...
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth
BioNTech SE BNTX reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus loss of $2.42 per share.
BioNTech Stock Rises as Drug Maker Beats Earnings Expectations.
The drug maker reported a narrower-than-expected loss in the second quarter.
BioNTech's Q2 revenues double on higher COVID vaccine sales
German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million), driven by higher revenues from its COVID-19 vaccine collaboration with P...
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update
Continued execution of BioNTech's oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates and BNT327, a bispecific antib...
Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
Pandemic darlings Moderna, BioNTech are now on two different paths
Covid-19 vaccine makers Moderna and BioNTech became household names almost overnight. Moderna and BioNTech have spent their Covid vaccine windfalls differently, with Moderna investing in its own mRNA ...
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union
NEW YORK and MAINZ, GERMANY, July 25, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency's (EMA) Committee for Medic...
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency's (EMA) Committee for Medici...
8MM Exanthema Market Report 2025-2034 | Rising Viral Infections and Diagnostic Innovations Across Major Markets Fueling Growth
The exanthema market is projected to grow from USD 1.39 billion in 2024 to USD 2.51 billion by 2034 at a CAGR of 6.10%. This growth is driven by rising viral infections and diagnostic innovations acro...
BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025
MAINZ, Germany, July 21, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2025 on Monday, August 4, 2025. Add...
BioNTech Announces Ryan Richardson to Step Down from the Management Board
MAINZ, Germany, July 17, 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Ryan Richardson will step down as Chief Strategy Officer in the Management...
Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win
Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents, in the latest round of a long-run...
5 Stocks To Ride The German Market Rally
Stocks in the United States have struggled to regain their February all-time highs amid the tariff uncertainty. In fact, the S&P 500 remains one of the worst-performing major stock indices in the deve...
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
BioNTech SE BNTX on Thursday agreed to acquire CureVac N.V. CVAC in an all-stock transaction.
BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.
CureVac stock soared 29% $5.26 in premarket trading immediately following the news.
BioNTech to acquire CureVac in $1.25 billion all-stock deal
German biotech firm BioNTech said on Thursday it agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares to boost its work on new mRNA-based cancer treatments.
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
MAINZ and TÜBINGEN, Germany, June 12, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into a definitiv...
RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts say
Health and Human Services Secretary Robert F. Kennedy Jr. has gutted a key government panel of vaccine advisors, a stunning move that some public health experts say undermines science, disrupts a trus...
Vaccine actions and policy positions under US Health Secretary Kennedy
U.S. Health Secretary Robert F. Kennedy Jr., a long-time vaccine skeptic, has been making sweeping changes to reshape U.S. regulation of vaccines, food and medicine.